Our Pricing

Wegovy UK Private Prescription: Complete Clinical Guide

Published on: June 03, 2026

Securing a wegovy uk private prescription online has become significantly more accessible as stock levels stabilise across UK pharmacies. At Cured Pharmacy, all Wegovy doses are available today from £79.00, with transparent upfront pricing and a free clinical assessment completed in under three minutes by our UK-registered prescribers.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the natural GLP-1 hormone, which regulates appetite through receptors in the brain and slows gastric emptying to promote earlier satiety.

In the landmark STEP 1 trial involving 1,961 participants, adults receiving Wegovy 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Approximately 86.4% of participants on Wegovy lost at least 5% of their baseline body weight, whilst 50.5% achieved weight loss of 15% or more [1]. These results represent the most substantial weight reduction outcomes observed in clinical trials for any licensed GLP-1 medication available through UK private prescription.

The medication works through multiple physiological pathways: reducing hunger signals in the hypothalamus, delaying stomach emptying to extend feelings of fullness, and improving glycaemic control through enhanced insulin secretion [2]. Patients typically report decreased food cravings and reduced portion sizes within the first fortnight of treatment, though individual responses vary and all outcomes remain subject to prescriber assessment and lifestyle modifications.

Wegovy Dosing Schedule and Titration Protocol

Wegovy follows a structured five-month dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic outcomes. The titration schedule begins with 0.25mg weekly for four weeks, progressing through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [2].

This gradual escalation approach significantly reduces the incidence of nausea and vomiting compared to starting at higher doses. In clinical trials, approximately 44% of participants experienced nausea during the escalation phase, though most cases were mild to moderate and resolved within several weeks as tolerance developed [1]. The structured titration also allows your UK prescriber to monitor your response at each stage and adjust the timeline if gastrointestinal symptoms prove persistent.

At Cured Pharmacy, all five dose strengths are currently in stock, ensuring uninterrupted treatment progression. Each pen delivers four weekly doses at the specified strength, with patients self-administering subcutaneous injections into the abdomen, thigh, or upper arm on the same day each week. Our clinical team provides comprehensive injection technique guidance during your consultation, and ongoing support remains available throughout your treatment journey.

Managing Missed Doses

If you miss a Wegovy dose and fewer than five days have elapsed since your scheduled injection day, administer the missed dose as soon as you remember, then resume your regular weekly schedule. If more than five days have passed, skip the missed dose entirely and inject your next dose on the regularly scheduled day [2]. Never double your dose to compensate for a missed injection, as this significantly increases the risk of gastrointestinal adverse effects.

Wegovy UK Private Prescription: Eligibility Criteria

To receive a wegovy uk private prescription online, you must meet specific clinical criteria established by the MHRA and supported by NICE guidance. Wegovy is licensed for adults aged 18 years and above with an initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease [2].

Your UK prescriber will conduct a comprehensive medical assessment reviewing your weight history, previous weight management attempts, current medications, and contraindications. Wegovy is not suitable during pregnancy or breastfeeding, for individuals with a personal or family history of medullary thyroid carcinoma, or those with multiple endocrine neoplasia syndrome type 2 [2]. Patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy require particularly careful evaluation before treatment initiation.

The consultation at Cured Pharmacy takes under three minutes to complete and includes questions about your medical history, current health status, and weight management goals. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team review every assessment to ensure Wegovy represents a safe and appropriate treatment option for your individual circumstances. All prescription medications dispensed through our pharmacy are subject to this clinical approval process, maintaining the same prescribing standards you would receive from your NHS GP.

Treatment Duration and Continuation Criteria

NICE recommends evaluating treatment response after 16 weeks on the maintenance dose. If you have not achieved at least 5% weight loss from baseline at this point, continuation of Wegovy may not be clinically appropriate and your prescriber will discuss alternative weight management strategies [3]. Most patients who respond well to treatment continue Wegovy for 12-24 months, though optimal duration remains individualised based on weight loss achieved, tolerability, and ongoing clinical benefit.

Common Side Effects and Clinical Management

Gastrointestinal symptoms represent the most frequently reported adverse effects with Wegovy, affecting approximately 44% of patients for nausea, 32% for diarrhoea, 25% for vomiting, and 24% for constipation during clinical trials [1]. These effects typically emerge during dose escalation and diminish significantly as your body adapts to the medication over several weeks.

To minimise gastrointestinal discomfort, our clinical team recommends eating smaller, more frequent meals rather than large portions, avoiding high-fat and spicy foods during the initial treatment phase, and ensuring adequate hydration throughout the day. Injecting Wegovy at bedtime rather than morning may also reduce daytime nausea for some patients. If symptoms prove particularly troublesome, your prescriber may extend the duration at your current dose before escalating further, allowing additional time for tolerance to develop.

Less common but more serious adverse effects require immediate medical attention and include persistent severe abdominal pain potentially indicating pancreatitis, visual changes, symptoms of thyroid nodules such as a lump in the neck or persistent hoarseness, or signs of gallbladder disease including yellowing of skin or eyes [2]. Wegovy may also increase heart rate by 1-4 beats per minute on average, so patients with pre-existing cardiovascular conditions require particularly careful monitoring throughout treatment [1].

Wegovy vs Alternative Weight Loss Treatments

Several GLP-1 receptor agonists and other weight loss medications hold MHRA licensing for chronic weight management in the UK, each with distinct mechanisms, efficacy profiles, and administration requirements. Understanding these differences helps you and your prescriber select the most appropriate treatment for your individual circumstances.

Semaglutide-based Wegovy produces greater average weight reduction than liraglutide-based alternatives in head-to-head clinical trials. The STEP 8 trial directly compared weekly semaglutide 2.4mg against daily liraglutide 3mg, demonstrating mean weight loss of 15.8% versus 6.4% respectively over 68 weeks [4]. However, daily injection frequency may suit some patients' preferences better than weekly administration.

Newer dual GIP/GLP-1 receptor agonists have demonstrated even greater weight reduction in clinical trials, with some patients achieving average losses exceeding 20% of baseline body weight [5]. These medications work through two complementary hormone pathways rather than GLP-1 alone, potentially offering enhanced efficacy for patients who require more substantial weight loss or have not responded adequately to single-pathway treatments. Your UK prescriber will discuss all licensed options during your consultation, considering your medical history, treatment goals, and individual response factors.

Combination with Lifestyle Modifications

Wegovy achieves optimal results when combined with a reduced-calorie diet and increased physical activity programme. In clinical trials, all participants received lifestyle intervention counselling alongside medication, and this comprehensive approach remains essential for sustainable weight management [1]. Your prescriber may recommend referral to a registered dietitian or structured weight management programme to support your treatment journey and maintain weight loss after medication discontinuation.

Wegovy Stock Availability and Pricing Transparency

Following significant supply constraints throughout 2023, Wegovy stock levels have stabilised considerably across UK pharmacies in 2024. At Cured Pharmacy, all five dose strengths—0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg—are currently available with same-day prescription processing and discreet next-day delivery across the UK.

We maintain transparent upfront pricing at £79.00 for Wegovy, with costs clearly displayed before you complete your clinical consultation. This pricing structure includes your medication, UK prescriber assessment, and delivery, with no hidden fees or subscription requirements. Many patients find our approach more straightforward than services requiring payment before knowing whether treatment will be approved or stock is available.

Your prescription remains valid for repeat supplies, allowing you to reorder directly through your account once your initial clinical assessment is complete. Our pharmacy team monitors your treatment progression and will contact you if any clinical review becomes necessary before dispensing subsequent supplies. For any questions about your Wegovy prescription, dosing schedule, or side effect management, our UK-registered clinical team remains available on (+44) 116 4646009 during business hours.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–218. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Wegovy is a prescription-only medication licensed for chronic weight management in adults meeting specific BMI criteria. Individual results vary and weight loss outcomes cannot be guaranteed. Always consult a qualified healthcare professional before starting any new medication. Side effects may occur; report persistent or severe symptoms to your prescriber immediately.